Back to search

Article

Biological and biosimilar medicinal products: safety and efficacy

2016-02-02

Abstract excerpt

Biological medicinal products are one of most innovative and promising methods of pharmacotherapy. During the last 20 years several original biological medicinal products have been registered and marketed. Their safety and efficacy have been investigated thoroughly at the level of pre-clinical and clinical studies. These are large, complex protein structures obtained through methods used in genetic engineering, or...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8f928b47-aa1f-5b07-aabc-2d4fd6e200c5
DOI
10.7287/peerj.preprints.1699v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Biological and biosimilar medicinal products: safety and efficacyDOI 10.7287/peerj.preprints.1699v1
Molecular Biosimilarity--A Paradigm ShiftSemantic proximity
Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trialsSemantic proximity
The importance of real-world data in evaluating the safety of biosimilars: a descriptive study of clinical practice in an oncohematological population.Semantic proximity
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopeniaSemantic proximity
Cytokines--protein structure and biological activity: a complex relationship with implications for biological assays and standardization.Semantic proximity
An Assessment of Biological Potency and Molecular Characteristics of Different Innovator and Noninnovator Interferon-Beta ProductsSemantic proximity
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for PharmacistsSemantic proximity
A New Venue of TNF TargetingSemantic proximity
Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin AmericaSemantic proximity
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia ASemantic proximity
Recent advances in developing specific therapies for haemophiliaSemantic proximity
Ethical and human subject burdens of trials conducted to evaluate biosimilarsSemantic proximity
Select a neighboring publication to make it the new centre.